m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00032)
Regulator Name E3 ubiquitin-protein ligase Hakai (CBLL1)
Synonyms
CBLL1; HAKAI; RNF188; EC 2.3.2.27; Casitas B-lineage lymphoma-transforming sequence-like protein 1; c-Cbl-like protein 1; RING finger protein 188; RING-type E3 ubiquitin transferase Hakai
    Click to Show/Hide
Gene Name CBLL1
Regulator Type WRITER ERASER READER
Regulator Link Click to View Full Information of This Regulator
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Matrix metalloproteinase-2 (MMP-2)
Amylin [Phase 4]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Amylin. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Amylin through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [2]
Prinomastat [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Prinomastat. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Prinomastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [3]
Marimastat [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Marimastat. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Marimastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [4]
Metastat [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Metastat. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Metastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [5]
Neovastat [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Neovastat. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Neovastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [6]
RO-26-2853 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for RO-26-2853. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of RO-26-2853 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [7]
2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [8]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [9]
3-(4-(2-phenylethynyl)benzoyl)pentanoic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [10]
3-(4-Phenylethynylbenzoyl)nonanoic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 3-(4-Phenylethynylbenzoyl)nonanoic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 3-(4-Phenylethynylbenzoyl)nonanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [8]
4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [11]
5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [12]
5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [13]
5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [14]
5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [14]
Cis-2-aminocyclohexylcarbamoylphosphonic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Cis-2-aminocyclohexylcarbamoylphosphonic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Cis-2-aminocyclohexylcarbamoylphosphonic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [15]
Clinopodic acid C [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Clinopodic acid C. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Clinopodic acid C through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [16]
Folate gamma-hydroxamic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Folate gamma-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Folate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [8]
Folate gamma-L-proline-hydroxamic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Folate gamma-L-proline-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Folate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [17]
IK-862 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for IK-862. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of IK-862 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [18]
Lithospermic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Lithospermic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Lithospermic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [19]
Methotrexate gamma-hydroxamic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Methotrexate gamma-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Methotrexate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [15]
Methotrexate gamma-L-proline-hydroxamic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Methotrexate gamma-L-proline-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Methotrexate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [15]
MMI270 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for MMI270. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of MMI270 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [20]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [21]
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [17]
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl). The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [22]
PD-169469 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for PD-169469. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of PD-169469 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [23]
PNU-107859 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for PNU-107859. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of PNU-107859 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [14]
Ro-37-9790 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Ro-37-9790. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Ro-37-9790 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [15]
Roche 28-2653 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Roche 28-2653. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Roche 28-2653 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [14]
SC-74020 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for SC-74020. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of SC-74020 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [24]
SR-973 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for SR-973. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of SR-973 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [9]
UK-356618 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for UK-356618. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of UK-356618 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [25]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [9]
BB-1101 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for BB-1101. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of BB-1101 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [26]
BB-3644 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for BB-3644. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of BB-3644 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [27]
BMS 275291 [Discontinued in Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for BMS 275291. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of BMS 275291 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [28]
CDP-845 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for CDP-845. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of CDP-845 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [29]
Galarubicin [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Galarubicin. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Galarubicin through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [30]
GM6001 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for GM6001. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of GM6001 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [31]
L-696418 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for L-696418. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of L-696418 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [6]
RS-130830 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for RS-130830. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of RS-130830 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [32]
SC-44463 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for SC-44463. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of SC-44463 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [33]
Tanomastat [Discontinued in Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Tanomastat. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Tanomastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [34]
Matrix metalloproteinase-9 (MMP-9)
Amylin [Phase 4]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Amylin. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Amylin through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [2]
Andecaliximab [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Andecaliximab. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Andecaliximab through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [35]
Curcumin [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Curcumin. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Curcumin through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [36]
DP-b99 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for DP-b99. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of DP-b99 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [37]
GS-5745 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for GS-5745. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of GS-5745 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [38]
BLZ-100 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for BLZ-100. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of BLZ-100 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [39]
Neovastat [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Neovastat. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Neovastat through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [40]
DX-2802 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for DX-2802. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of DX-2802 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [7]
2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [23]
2-(biphenyl-4-ylsulfonamido)pentanedioic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-(biphenyl-4-ylsulfonamido)pentanedioic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 2-(biphenyl-4-ylsulfonamido)pentanedioic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [41]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [9]
2-Amino-N,3,3-Trimethylbutanamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-Amino-N,3,3-Trimethylbutanamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 2-Amino-N,3,3-Trimethylbutanamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [24]
3-(4-(2-phenylethynyl)benzoyl)pentanoic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [42]
3-(4-Phenylethynylbenzoyl)nonanoic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 3-(4-Phenylethynylbenzoyl)nonanoic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 3-(4-Phenylethynylbenzoyl)nonanoic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [8]
4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [16]
5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [14]
5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [13]
5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [14]
5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [14]
5-Methyl-5-phenyl-pyrimidine-2,4,6-trione [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-Methyl-5-phenyl-pyrimidine-2,4,6-trione. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of 5-Methyl-5-phenyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [14]
ARP100 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for ARP100. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of ARP100 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [43]
Carboxylated glucosamine [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Carboxylated glucosamine. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Carboxylated glucosamine through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [10]
Folate gamma-hydroxamic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Folate gamma-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Folate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [15]
IK-862 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for IK-862. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of IK-862 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [18]
Methotrexate gamma-hydroxamic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Methotrexate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [17]
Methotrexate gamma-L-phenylalaninehydroxamic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-L-phenylalaninehydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Methotrexate gamma-L-phenylalaninehydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [8]
Methotrexate gamma-L-proline-hydroxamic acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-L-proline-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Methotrexate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [15]
MMI270 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for MMI270. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of MMI270 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [27]
N-hydroxy-2,3-bis(phenylsulfonamido)propanamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-hydroxy-2,3-bis(phenylsulfonamido)propanamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of N-hydroxy-2,3-bis(phenylsulfonamido)propanamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [9]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [21]
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [17]
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl). The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [15]
Ro 28-2653 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Ro 28-2653. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Ro 28-2653 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [24]
Ro-37-9790 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Ro-37-9790. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Ro-37-9790 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [15]
Roche 28-2653 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Roche 28-2653. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Roche 28-2653 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [14]
SL422 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for SL422. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of SL422 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [44]
SR-973 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for SR-973. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of SR-973 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [9]
UK-356618 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for UK-356618. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of UK-356618 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [25]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [45]
CDP-845 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for CDP-845. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of CDP-845 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [46]
CT-1746 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for CT-1746. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of CT-1746 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [47]
Galarubicin [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Galarubicin. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Galarubicin through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [48]
GM6001 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for GM6001. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of GM6001 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [31]
RO-319790 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for RO-319790. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of RO-319790 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [49]
RS-130830 [Discontinued in Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for RS-130830. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of RS-130830 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [32]
SC-44463 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for SC-44463. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of SC-44463 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [33]
References
Ref 1 CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019 Jun;10(6):1479-1488. doi: 10.1111/1759-7714.13097. Epub 2019 May 23.
Ref 2 Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem. 2013 Feb 1;288(5):3553-9. doi: 10.1074/jbc.M112.438457. Epub 2012 Dec 10.
Ref 3 Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
Ref 4 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
Ref 5 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4. doi: 10.1016/j.bmcl.2009.05.111. Epub 2009 Jun 2.
Ref 6 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. doi: 10.1021/jm0308038.
Ref 7 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6. doi: 10.1016/j.bmcl.2004.12.016.
Ref 8 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. doi: 10.1021/jm051101g.
Ref 9 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. J Med Chem. 2009 Oct 22;52(20):6347-61. doi: 10.1021/jm900335a.
Ref 10 Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100. doi: 10.1016/j.bmcl.2006.03.065. Epub 2006 May 2.
Ref 11 Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31. doi: 10.1021/jm050787+.
Ref 12 A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations. J Med Chem. 2004 Jun 3;47(12):3065-74. doi: 10.1021/jm030570k.
Ref 13 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. J Med Chem. 2002 Nov 7;45(23):4954-7. doi: 10.1021/jm0255670.
Ref 14 Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. doi: 10.1016/s0960-894x(01)00104-4.
Ref 15 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. doi: 10.1016/j.bmc.2006.11.017. Epub 2006 Nov 14.
Ref 16 Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6. doi: 10.1016/s0960-894x(99)00259-0.
Ref 17 Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5. doi: 10.1016/j.bmc.2007.09.014. Epub 2007 Sep 14.
Ref 18 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
Ref 19 Matrix metalloproteinase-2 inhibitors from Clinopodium chinense var. parviflorum. J Nat Prod. 2009 Aug;72(8):1379-84. doi: 10.1021/np800781t.
Ref 20 Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. doi: 10.1038/nrc1821.
Ref 21 The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. doi: 10.1016/j.bmcl.2009.07.155. Epub 2009 Aug 6.
Ref 22 Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem. 2008 Mar 13;51(5):1406-14. doi: 10.1021/jm701087n. Epub 2008 Feb 8.
Ref 23 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. doi: 10.1016/j.bmcl.2006.01.055. Epub 2006 Feb 10.
Ref 24 The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96. doi: 10.1038/sj.onc.1205267.
Ref 25 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 26 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
Ref 27 Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29. doi: 10.2165/00126839-199901020-00001.
Ref 28 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72. doi: 10.1038/nrc884.
Ref 29 Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8. doi: 10.1016/s0960-894x(98)00255-8.
Ref 30 Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:44-6. doi: 10.1111/j.1525-1438.2007.01105.x.
Ref 31 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. doi: 10.1016/s0093-7754(01)90035-1.
Ref 32 Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31. doi: 10.1016/j.bcp.2005.10.007. Epub 2005 Nov 2.
Ref 33 Gelatinase inhibitors: a patent review (2011-2017). Expert Opin Ther Pat. 2018 Jan;28(1):31-46. doi: 10.1080/13543776.2018.1397132. Epub 2017 Nov 12.
Ref 34 Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8. doi: 10.1002/cncr.23108.
Ref 35 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. Bioorg Med Chem. 2009 Feb 1;17(3):1290-6. doi: 10.1016/j.bmc.2008.12.029. Epub 2009 Jan 6.
Ref 36 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789. doi: 10.1371/journal.pone.0099789. eCollection 2014.
Ref 37 Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. J Med Chem. 2001 Oct 11;44(21):3347-50. doi: 10.1021/jm015533c.
Ref 38 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. doi: 10.1021/jm010127e.
Ref 39 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 40 National Cancer Institute Drug Dictionary (drug id 747683).
Ref 41 Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. doi: 10.1016/j.bmc.2008.03.018. Epub 2008 Mar 8.
Ref 42 Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3105-10. doi: 10.1016/j.bmcl.2006.03.077. Epub 2006 Apr 17.
Ref 43 Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem. 2004 Apr 8;47(8):1930-8. doi: 10.1021/jm0304313.
Ref 44 Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg Med Chem. 2006 Jun 15;14(12):4260-76. doi: 10.1016/j.bmc.2006.01.056. Epub 2006 Feb 17.
Ref 45 Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7. doi: 10.1016/j.bmcl.2008.04.035. Epub 2008 Apr 16.
Ref 46 Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis. 1997 Mar;15(2):184-95. doi: 10.1023/a:1018461112732.
Ref 47 The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8. doi: 10.1016/s0960-894x(98)00186-3.
Ref 48 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. doi: 10.1038/s41573-019-0013-8.
Ref 49 Clinical pipeline report, company report or official report of DeepDyve.